Newsbenzinga
Arrowhead Achieves Clinical Validation for New Drug Platform
· Published
Article summary
Arrowhead Pharmaceuticals reports interim Phase 1/2a data for ARO-DIMER-PA, demonstrating dual-gene silencing to treat high fat in blood.
An excerpt from the original article.
Comments —
Loading comments…